Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB(*) infections

Effectiveness of the 50-μg mRNA-1273.214 bivalent vaccine against SARS-CoV-2 infection was modest at 25% in a matched, retrospective, cohort study in Qatar comparing infection incidence in the bivalent cohort to that in the national no-recent-vaccination resident cohort. XBB* immune evasion, immune...

Descripción completa

Detalles Bibliográficos
Autores principales: Chemaitelly, Hiam, Ayoub, Houssein H, AlMukdad, Sawsan, Faust, Jeremy S, Tang, Patrick, Coyle, Peter, Yassine, Hadi M, Al Thani, Asmaa A, Al-Khatib, Hebah A, Hasan, Mohammad R, Al-Kanaani, Zaina, Al-Kuwari, Einas, Jeremijenko, Andrew, Kaleeckal, Anvar H, Latif, Ali N, Shaik, Riyazuddin M, Abdul-Rahim, Hanan F, Nasrallah, Gheyath K, Al-Kuwari, Mohamed G, Butt, Adeel A, Al-Romaihi, Hamad E, Al-Thani, Mohamed H, Al-Khal, Abdullatif, Bertollini, Roberto, Abu-Raddad, Laith J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481416/
https://www.ncbi.nlm.nih.gov/pubmed/37555656
http://dx.doi.org/10.1093/jtm/taad106
_version_ 1785101970262982656
author Chemaitelly, Hiam
Ayoub, Houssein H
AlMukdad, Sawsan
Faust, Jeremy S
Tang, Patrick
Coyle, Peter
Yassine, Hadi M
Al Thani, Asmaa A
Al-Khatib, Hebah A
Hasan, Mohammad R
Al-Kanaani, Zaina
Al-Kuwari, Einas
Jeremijenko, Andrew
Kaleeckal, Anvar H
Latif, Ali N
Shaik, Riyazuddin M
Abdul-Rahim, Hanan F
Nasrallah, Gheyath K
Al-Kuwari, Mohamed G
Butt, Adeel A
Al-Romaihi, Hamad E
Al-Thani, Mohamed H
Al-Khal, Abdullatif
Bertollini, Roberto
Abu-Raddad, Laith J
author_facet Chemaitelly, Hiam
Ayoub, Houssein H
AlMukdad, Sawsan
Faust, Jeremy S
Tang, Patrick
Coyle, Peter
Yassine, Hadi M
Al Thani, Asmaa A
Al-Khatib, Hebah A
Hasan, Mohammad R
Al-Kanaani, Zaina
Al-Kuwari, Einas
Jeremijenko, Andrew
Kaleeckal, Anvar H
Latif, Ali N
Shaik, Riyazuddin M
Abdul-Rahim, Hanan F
Nasrallah, Gheyath K
Al-Kuwari, Mohamed G
Butt, Adeel A
Al-Romaihi, Hamad E
Al-Thani, Mohamed H
Al-Khal, Abdullatif
Bertollini, Roberto
Abu-Raddad, Laith J
author_sort Chemaitelly, Hiam
collection PubMed
description Effectiveness of the 50-μg mRNA-1273.214 bivalent vaccine against SARS-CoV-2 infection was modest at 25% in a matched, retrospective, cohort study in Qatar comparing infection incidence in the bivalent cohort to that in the national no-recent-vaccination resident cohort. XBB* immune evasion, immune imprinting effects, or both, may explain findings.
format Online
Article
Text
id pubmed-10481416
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-104814162023-09-07 Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB(*) infections Chemaitelly, Hiam Ayoub, Houssein H AlMukdad, Sawsan Faust, Jeremy S Tang, Patrick Coyle, Peter Yassine, Hadi M Al Thani, Asmaa A Al-Khatib, Hebah A Hasan, Mohammad R Al-Kanaani, Zaina Al-Kuwari, Einas Jeremijenko, Andrew Kaleeckal, Anvar H Latif, Ali N Shaik, Riyazuddin M Abdul-Rahim, Hanan F Nasrallah, Gheyath K Al-Kuwari, Mohamed G Butt, Adeel A Al-Romaihi, Hamad E Al-Thani, Mohamed H Al-Khal, Abdullatif Bertollini, Roberto Abu-Raddad, Laith J J Travel Med Rapid Communication Effectiveness of the 50-μg mRNA-1273.214 bivalent vaccine against SARS-CoV-2 infection was modest at 25% in a matched, retrospective, cohort study in Qatar comparing infection incidence in the bivalent cohort to that in the national no-recent-vaccination resident cohort. XBB* immune evasion, immune imprinting effects, or both, may explain findings. Oxford University Press 2023-08-09 /pmc/articles/PMC10481416/ /pubmed/37555656 http://dx.doi.org/10.1093/jtm/taad106 Text en © International Society of Travel Medicine 2023. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Rapid Communication
Chemaitelly, Hiam
Ayoub, Houssein H
AlMukdad, Sawsan
Faust, Jeremy S
Tang, Patrick
Coyle, Peter
Yassine, Hadi M
Al Thani, Asmaa A
Al-Khatib, Hebah A
Hasan, Mohammad R
Al-Kanaani, Zaina
Al-Kuwari, Einas
Jeremijenko, Andrew
Kaleeckal, Anvar H
Latif, Ali N
Shaik, Riyazuddin M
Abdul-Rahim, Hanan F
Nasrallah, Gheyath K
Al-Kuwari, Mohamed G
Butt, Adeel A
Al-Romaihi, Hamad E
Al-Thani, Mohamed H
Al-Khal, Abdullatif
Bertollini, Roberto
Abu-Raddad, Laith J
Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB(*) infections
title Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB(*) infections
title_full Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB(*) infections
title_fullStr Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB(*) infections
title_full_unstemmed Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB(*) infections
title_short Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB(*) infections
title_sort bivalent mrna-1273.214 vaccine effectiveness against sars-cov-2 omicron xbb(*) infections
topic Rapid Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481416/
https://www.ncbi.nlm.nih.gov/pubmed/37555656
http://dx.doi.org/10.1093/jtm/taad106
work_keys_str_mv AT chemaitellyhiam bivalentmrna1273214vaccineeffectivenessagainstsarscov2omicronxbbinfections
AT ayoubhousseinh bivalentmrna1273214vaccineeffectivenessagainstsarscov2omicronxbbinfections
AT almukdadsawsan bivalentmrna1273214vaccineeffectivenessagainstsarscov2omicronxbbinfections
AT faustjeremys bivalentmrna1273214vaccineeffectivenessagainstsarscov2omicronxbbinfections
AT tangpatrick bivalentmrna1273214vaccineeffectivenessagainstsarscov2omicronxbbinfections
AT coylepeter bivalentmrna1273214vaccineeffectivenessagainstsarscov2omicronxbbinfections
AT yassinehadim bivalentmrna1273214vaccineeffectivenessagainstsarscov2omicronxbbinfections
AT althaniasmaaa bivalentmrna1273214vaccineeffectivenessagainstsarscov2omicronxbbinfections
AT alkhatibhebaha bivalentmrna1273214vaccineeffectivenessagainstsarscov2omicronxbbinfections
AT hasanmohammadr bivalentmrna1273214vaccineeffectivenessagainstsarscov2omicronxbbinfections
AT alkanaanizaina bivalentmrna1273214vaccineeffectivenessagainstsarscov2omicronxbbinfections
AT alkuwarieinas bivalentmrna1273214vaccineeffectivenessagainstsarscov2omicronxbbinfections
AT jeremijenkoandrew bivalentmrna1273214vaccineeffectivenessagainstsarscov2omicronxbbinfections
AT kaleeckalanvarh bivalentmrna1273214vaccineeffectivenessagainstsarscov2omicronxbbinfections
AT latifalin bivalentmrna1273214vaccineeffectivenessagainstsarscov2omicronxbbinfections
AT shaikriyazuddinm bivalentmrna1273214vaccineeffectivenessagainstsarscov2omicronxbbinfections
AT abdulrahimhananf bivalentmrna1273214vaccineeffectivenessagainstsarscov2omicronxbbinfections
AT nasrallahgheyathk bivalentmrna1273214vaccineeffectivenessagainstsarscov2omicronxbbinfections
AT alkuwarimohamedg bivalentmrna1273214vaccineeffectivenessagainstsarscov2omicronxbbinfections
AT buttadeela bivalentmrna1273214vaccineeffectivenessagainstsarscov2omicronxbbinfections
AT alromaihihamade bivalentmrna1273214vaccineeffectivenessagainstsarscov2omicronxbbinfections
AT althanimohamedh bivalentmrna1273214vaccineeffectivenessagainstsarscov2omicronxbbinfections
AT alkhalabdullatif bivalentmrna1273214vaccineeffectivenessagainstsarscov2omicronxbbinfections
AT bertolliniroberto bivalentmrna1273214vaccineeffectivenessagainstsarscov2omicronxbbinfections
AT aburaddadlaithj bivalentmrna1273214vaccineeffectivenessagainstsarscov2omicronxbbinfections

Ejemplares similares